Evidence map›Paper›PMID 31015873›Full record

ArticlePharmacy practice

Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review.

Fabiana R Varallo, Victória Trombotto, Rosa C Lucchetta, Patricia de C Mastroianni

Open access · diamondAbstract read
In one paragraph

Article in Pharmacy practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. [Paediatric Life Support].Notfall & rettungsmedizin · 2021
    Review
  6. What would be a trigger tool with better performance for detecting drug-induced hyperkalemia?Sao Paulo medical journal = Revista paulista de medicina · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Fabiana R VaralloAmerico Brasiliense State Hospital, Américo Brasiliense. Araraquara SP (Brazil). varallo.f.r@gmail.com.ORCID 0000-0003-4016-1442
Victória TrombottoDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP). Araraquara, SP (Brazil). victoriatrombotto@gmail.com.ORCID 0000-0002-8307-0359
Rosa C LucchettaDepartment of Pharmacy, Federal University of Paraná. Curitiba (Brazil). rc.lucch@yahoo.com.br.ORCID 0000-0002-4004-1320
Patricia de C MastroianniDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP). Araraquara, SP (Brazil). pmastro@fcfar.unesp.br.ORCID 0000-0001-8467-7278
Centro Universitário de Araraquara · BRInstituto Brasiliense de Otorrinolaringologia · BRUniversidade Federal do Paraná · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the management of hyperkalemia follows expert guidelines, treatment approaches are based on traditionally accepted practice standards. New drugs have been assessed such as sodium zirconium cyclosilicate and patiromer; however, their safety and efficacy or effectiveness have not yet been compared to traditional pharmacotherapy.

objectiveThe present systematic review had the purpose to evaluate the efficacy, effectiveness, and safety of hyperkalemia pharmacotherapies.

methodsPubMed, LILACS, Cochrane Library, and ClinicalTrials were searched through November 2018. Clinical trial, cohort and case-control were searched. The risk of bias (RoB v2.0 and ROBINS-I) and quality of evidence (GRADE) at the level of outcomes were assessed.

resultsSixteen clinical trials and one retrospective cohort were identified regarding efficacy and safety of 24 different alternatives. The management of hyperkalemia remains empirical and off-label, since sodium zirconium cyclosilicate and patiromer are not available in several countries and further studies are required to assess efficacy, effectiveness and safety. Sodium or calcium polystyrene sulfonate (moderate confidence), sodium zirconium cyclosilicate (moderate confidence), and insulin plus dextrose (moderate confidence) showed superior efficacy to, respectively, placebo, no treatment, placebo, and dextrose. Other therapies (low confidence) showed similar efficacy compared to active or inactive alternatives. Most of the adverse events reported were nonspecific, so it was not possible to assign the cause and to classify as defined or probable.

conclusionsComparative cohort and case-control studies are need to evaluate the safety and effectiveness of new and traditional pharmacotherapies to support the development of guidelines about acute and chronic hyperkalemia, with high-quality evidence.

Indexed as

HyperkalemiaPolymersPotassiumRenal InsufficiencySilicatesSystematic Reviews as TopicTreatment Outcome

Identifiers

PMID31015873
PMCPMC6463413
OpenAlexW2918798388

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.